86 results
8-K
EX-99.1
PHIO
Phio Pharmaceuticals Corp
2 Apr 24
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
7:30am
have completed treatment with PH-762 with no reported adverse events.
We now have four investigation sites under contract to participate in the trial
8-K
EX-10.1
797uxy23okhhnlu
26 Jul 23
Departure of Directors or Certain Officers
4:30pm
8-K
EX-10.1
f0jjj04uihi2
2 Jun 23
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct
4:30pm
8-K
EX-10.2
vtkocdyrz6 4ny4fy6b
2 Jun 23
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct
4:30pm
8-K
EX-10.3
mkj1z8lsf5
2 Jun 23
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct
4:30pm
8-K
EX-10.1
4ucc0yd6bt
20 Apr 23
Phio Pharmaceuticals Announces $2 Million Registered Direct
2:53pm
8-K
EX-10.1
svp 50w89p
16 Nov 22
Entry into a Material Definitive Agreement
5:00pm
8-K
EX-10.1
wyept 1b10mn1k
17 Feb 21
Entry into a Material Definitive Agreement
4:15pm
8-K
EX-5.1
98fv4w ghd0
17 Feb 21
Entry into a Material Definitive Agreement
4:15pm